U.S. markets closed

Citius Pharmaceuticals, Inc. (CTXR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0800-0.0600 (-2.80%)
At close: 4:00PM EDT
2.1000 ++0.02 (+0.96%)
After hours: 07:01PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.1400
Open2.1100
Bid2.0700 x 46000
Ask2.1200 x 3000
Day's Range2.0700 - 2.1400
52 Week Range0.8730 - 4.5600
Volume1,826,596
Avg. Volume5,216,815
Market Cap303.636M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Citius Pharmaceuticals, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, neuroscience drug Lyrica, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor, representing over a fifth of total firm sales.
    Rating
    Fair Value
    Economic Moat
    11 months agoMorningstar
View more